Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine; Drug: Quizartinib Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Research